Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer

NCT07765433 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT07765433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07765433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized Study of Ivonescimab With Gemcitabine and Cisplatin Versus Standard of Care Chemoimmunotherapy in Advanced Biliary Tract Cancer
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
January 11, 2027
Completion date
December 31, 2029
Enrollment
336 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced biliary tract adenocarcinoma, locally advanced extrahepatic cholangiocarcinoma, locally advanced intrahepatic cholangiocarcinoma, locally advanced unresectable gallbladder adenocarcinoma, metastatic biliary tract adenocarcinoma, metastatic extrahepatic cholangiocarcinoma, metastatic gallbladder adenocarcinoma, metastatic intrahepatic cholangiocarcinoma, stage iii distal bile duct cancer ajcc v8, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iv distal bile duct cancer ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8, unresectable biliary tract adenocarcinoma, unresectable extrahepatic cholangiocarcinoma, unresectable intrahepatic cholangiocarcinoma